DYOR. Analysis presented here is not intended as financial advice. You must do your own research, make your own assessment of investing risk and make your own investment decisions.The $5.4M raise funds the company for accelerating trial activities. The options are expected to inject a further $31.7M of funds over the next 12 months to well-fund activities through 2022 and beyond.
The result is that the fully-diluted share issue moves from approximately 162M to 171M.
My previous valuations were conservatively using 200M fully-diluted, however I think this new funding allows me to reduce fully-diluted estimate to 180M shares. This allows for a potential future raise if needed, although this is unlikely to occur until after 2024 or alternatively if a strategic investor later joined the register. This allowance of an additional ~9M shares helps offset potential fluctuations in the exchange rate used in my valuations.
The net effect is that previous valuations are lifted by approximately 10%.
So ...
... based on Leukeamia indications and buyout of Forty Seven = fair value for buyout $35 per share
... based on Breast Cancer indication and buyout of Immunomedics = fair value for buyout $151 per share
Using a risked NPV approach factoring probability of success of the 3 pillars, current risk-adjusted value is for a buyout is $93.
RACE still have a long way to go but they are entering the sweet spot for a transaction. Many M&A transactions occur during Phase I and Phase II.
![]()
This is the current RACE activity timeline, as you can see RACE are moving trials into Phase I and II. These are designed to leverage the historic safety and efficacy of Bisantrene.
![]()
I put price targets for potential partnership at $8 to $14 per share. This is roughly based on partnerships implemented by peers with strong efficacy.
![]()
Calculations and assumptions for NPV analysis below. Although not shown in RAC's current activity timeline we are waiting for further data on Ovarian Cancer and Breast Cancer ( publishing of preclinical results in a journal ), for this reason I have included Ovarian Cancer in the NPV analysis.
![]()
![]()
Peer analysis for partnerships.
![]()
Analysis of peer buyouts, mapped to RACE Pillars.
![]()
It is worth noting what happened with Synthorx. A transaction of this scale would have an implied value of at least $9 per share. Note that the transaction occurred early in Phase I and before the trial reported results.
![]()
- Forums
- ASX - By Stock
- RAC
- Ann: Race investor briefing & updated presentation
Ann: Race investor briefing & updated presentation, page-7
-
- There are more pages in this discussion • 328 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.70 |
Change
0.050(3.03%) |
Mkt cap ! $289.6M |
Open | High | Low | Value | Volume |
$1.66 | $1.70 | $1.63 | $181.9K | 109.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 11946 | $1.70 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.75 | 27579 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6605 | 1.635 |
1 | 10752 | 1.615 |
2 | 20016 | 1.610 |
2 | 21000 | 1.600 |
1 | 1279 | 1.555 |
Price($) | Vol. | No. |
---|---|---|
1.750 | 14579 | 3 |
1.755 | 990 | 1 |
1.760 | 500 | 1 |
1.800 | 824 | 2 |
1.820 | 4000 | 3 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online